Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
In Malta, the financing of drug-related activities is decided annually by the entities in charge of their implementation. The information available is limited and does not permit reporting on the size and trends of drug-related expenditure. Notwithstanding, the National Drugs Policy stresses the importance of identifying the funds required for implementing the planned actions. The government supplements funding for drug-related programmes from funds seized through the Prevention of Money Laundering Act.
The most recent estimate, for 2012, indicated that Malta spent an estimated EUR 5.5 million on drug reduction activities, and that drug-related expenditure amounted to approximately 0.08 % of gross domestic product (GDP). However, it is not known what proportion of all drug-related expenditure this represents.